TMO Today - Aug 11: Mixed Reactions to FDA News

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

TMO Today - Aug 11: Mixed Reactions to FDA News

無料で聴く

ポッドキャストの詳細を見る

Hey there! It’s Joey here, your friendly longtime investor, breaking down the day for you. Today, we’re looking at Thermo Fisher Scientific, or TMO for short. It was kind of a mixed bag day, finishing just a smidge in the green, up a tiny 0.15%.

So, what went down? Well, TMO barely moved, but there were some interesting things happening behind the scenes. The stock saw a bit of action with some big names selling off shares. The CEO, Marc Casper, sold a chunk of his stock—over 4,600 shares, which is a big deal. I mean, when the top dog is cashing out, it can raise some eyebrows, right? Then there’s Handelsbanken Fonder AB cutting back on their holdings too. Not exactly the confidence boost you want to see.

But here’s where it gets interesting: Investors were buzzing about a new FDA clearance for TMO’s multiple myeloma platform. This is a major deal in the biotech world, and you’d think that would send the stock soaring. But instead, it felt like people were still weighing the news against those sell-offs. So, we got this weird vibe of excitement mixed with caution. That one stung a bit for some.

Looking ahead, TMO’s got a lot on its plate, especially with the new product launch coming soon. It'll be interesting to see how that plays out and if it gets people feeling more positive about the stock.

Alright, that’s the scoop for today! Just remember, this is all for your info and entertainment—no financial advice here. Catch you later!

まだレビューはありません